| NEKTAR THERAPEUTICS |
| USA |
| Gesundheit |
| US6402683063 / A419UB |
| ITH0 (Frankfurt) / NKTR (NASDAQ) |
| FRA:ITH0, ETR:ITH0, ITH0:GR, NASDAQ:NKTR |
| - |
| https://www.nektar.com/ |
|
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States an..
>Volltext.. |
| 1796 Mio. EUR |
| 1428.44 Mio. EUR |
| 48.5 Mio. EUR |
| -108.02 Mio. EUR |
| -137.82 Mio. EUR |
| -7.34 EUR |
| 125.03 Mio. EUR |
| 114.95 Mio. EUR |
| -177.62 Mio. EUR |
| 9.85 |
| -40.29% |
| -11.27% |
| - |
| - |
| - |
| 2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 1.352.286 Euro. |
| NEKTAR THERAPEUTICS, NEKTAR THERAPEUTIC |
| 21.06.26 |
|
||||
|